Pharm Exec profiles its 2022 Emerging Pharma Leaders.
Click on the links below to read the profiles of Pharm Exec's 2022 Emerging Pharma Leaders.
Naveen Bazaj, Head of Corporate Development, Alector
Gardner Gendron, Chief/US Head of Commercial, NS Pharma
Aida Habtezion, MD, Senior VP, Chief Medical Officer, and Head of Worldwide Medical and Safety, Pfizer
Matthew J. Hawryluk, PhD, Executive VP, Chief Business Officer and Cambridge Site Head, Gritstone bio
Charmaine Lykins, Chief Commercial Officer, Karuna Therapeutics
Divya Chadha Manek, Senior Vice President of Clinical Development, Eyebiotech Limited (EyeBio)
Susan Pandya, MD, Vice President, Clinical Development, and Head of Cancer Metabolism Global Development Oncology and Immuno-Oncology, Servier Pharmaceuticals
Matthew R. Price, Co-Founder, Executive Vice President, Chief Operating Officer, and Board Director, Promontory Therapeutics
Quiona Russell, PhD, Associate Director of Medical Information and Medical Communication, G1 Therapeutics
Patricia Torr, US President and General Manager, Idorsia Pharmaceuticals
Shetal Vyas, Vice President of Operations, Ferring Pharmaceuticals
*From a pool of nominations, these final selections were judged in a blinded process by three Pharmaceutical Executive Editorial Advisory Board members and a former EPL. Selections were based on a number of criteria and review of professional accomplishments and progression of responsibilities in line with executives most likely to inhabit key “c-suite” functions.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.